Form 4 for PHVS Pharvaris N.V.
Accepted 2026-05-01 19:09:43 ET · period of report 2026-04-29 · accession 0001193125-26-201906 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-05-01 19:09 | 2026-04-29+ | PHVS | Lu Peng | Chief Medical Off | M - OptEx | $2.59 | +18.7K | 81.1K | +30% | +$48.5K |
| DMT | 2026-05-01 19:09 | 2026-04-29+ | PHVS | Lu Peng | Chief Medical Off | S - Sale+OE | $30.21 | -18.7K | 66.1K | -22% | -$565.9K |
| DMT | 2026-05-01 19:09 | 2026-04-29+ | PHVS | Lu Peng | Chief Medical Off | M - OptEx | $0.00 | -18.7K | 219.5K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-29 | M | A | 3,733 | $2.59 | 69,816 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. |
| 2 | Common | Common Stock | 2026-04-29 | S | D | 3,733 | $30.06 | 62,350 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. (F2) The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.20. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2026-04-30 | M | A | 15,000 | $2.59 | 81,083 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. |
| 4 | Common | Common Stock | 2026-04-30 | S | D | 15,000 | $30.24 | 66,083 | D | — | — | (F1) This is a scheduled exercise and sale from 10b5-1 trading plan. (F3) The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.75 to $30.2418. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-04-29 | M | D | 3,733 | $0.00 | 234,474 | D | $2.59 · — to 2030-02-03 | 3,733 Common Stock | (F4) 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. (F5) The number of derivative securities beneficially owned following the reported transaction has been updated to correct an error in the number of options remaining from this grant as previously reported. This correction does not reflect a new transaction. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-04-30 | M | D | 15,000 | $0.00 | 219,474 | D | $2.59 · — to 2030-02-03 | 15,000 Common Stock | (F4) 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. (F5) The number of derivative securities beneficially owned following the reported transaction has been updated to correct an error in the number of options remaining from this grant as previously reported. This correction does not reflect a new transaction. |